Advertisement

Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis

  • Jianzhong Zhang
  • Xiao Li
  • Bin Yang
  • Cheng Wu
  • Yanghua Fan
  • Hongjun Li
Original Article
  • 137 Downloads

Abstract

Purpose

Recently, several randomized controlled trials (RCTs) explored the effects of α-blockers with or without phosphodiesterase type 5 inhibitors (PDE5-Is) for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). However, the results were inconsistent. We performed this meta-analysis to evaluate the role of combination therapy (α-blockers and PDE5-Is) in patients with LUTS/BPH.

Materials and methods

Databases including PubMed, Cochrane library, Web of Science, and Embase were searched for qualified RCTs. Pooled mean differences (MDs) and odds ratios (ORs) were calculated to measure the effects and adverse events in combination therapy. Moreover, subgroup analyses of ethnicity, dosage of PDE5-Is, treatment duration, and severity of LUTS/BPH were performed. In addition, trial sequential analyses (TSAs) were used to assess whether the evidence for the results was sufficient.

Results

Overall, this study identified 11 eligible RCTs, including 855 LUTS/BPH patients. Patients receiving combination therapy had better improvement in international prostate symptom score (IPSS: MD: 1.66, 95% CI − 3.03 to − 0.29), maximum urinary flow rate (Qmax: MD: 0.94, 95% CI 0.24–1.64), and international index of erectile function (IIEF: MD: 4.73, 95% CI 2.95–6.51), comparing those without PDE5-Is. Besides, subgroup analyses indicated that the effects of combination treatment were associated with ethnicity, treatment duration, and severity of LUTS/BPH. By TSA, the findings in the current study were based on sufficient evidence.

Conclusions

Our results indicated that combination therapy can significantly improve IPSS, Qmax, and IIEF in patients with LUTS/BPH. Combination therapy might be more suitable for these patients.

Keywords

Lower urinary tract symptom Benign prostatic hyperplasia Phosphodiesterase type 5 inhibitor α-Blocker 

Notes

Acknowledgements

This work is supported by the grant from the National Natural Science Foundation of China (81671488) and the Beijing Natural Science Foundation (Grant No. 7162152).

Author’s contribution

HJL: project development and manuscript writing. JZZ: data collection and manuscript writing. XL: data collection and data analysis. BY: data collection and data analysis. CW: data collection. YHF.: data analysis.

Funding

This study was funded by the National Natural Science Foundation of China (81671488) and the Beijing Natural Science Foundation (Grant no. 7162152).

Compliance with ethical standards

Conflict of interest

Hongjun Li has received research grants from the National Natural Science Foundation of China (81671488) and the Beijing Natural Science Foundation (Grant no. 7162152).

Informed consent

Informed consent was obtained from all individual participants included in the study.

Research involving human participants and/or animals

For this type of study formal consent is not required. This article does not contain any studies with animals performed by any of the authors.

Supplementary material

345_2018_2370_MOESM1_ESM.tif (1.1 mb)
Figure S1 Subgroup analyses of effects of combination therapy versus a-blockers alone by assessment of IPSS. A–D Subgroup analyses by ethnicity, treatment period, severity of LUTS, and dosage of PDE5-Is, respectively (TIFF 1091 kb)
345_2018_2370_MOESM2_ESM.tif (437 kb)
Figure S2 Subgroup analyses of effects of combination therapy versus a-blockers alone by assessment of Qmax. A–C Subgroup analyses by treatment period, severity of LUTS, and dosage of PDE5-Is, respectively (TIFF 438 kb)
345_2018_2370_MOESM3_ESM.tif (475 kb)
Figure S3 Subgroup analyses of effects of combination therapy versus a-blockers alone by assessment of PVR. A, B Subgroup analyses by treatment period and dosage of PDE5-Is, respectively (TIFF 476 kb)
345_2018_2370_MOESM4_ESM.tif (499 kb)
Figure S4 Subgroup analyses of effects of combination therapy versus a-blockers alone by assessment of IIEF. A, B Subgroup analyses by treatment period and dosage of PDE5-Is, respectively (TIFF 500 kb)
345_2018_2370_MOESM5_ESM.tif (549 kb)
Figure S5 Sensitivity of each included study in this meta-analysis. A–D indicated sensitivity analyses of IPSS, Qmax, PVR, and IIEF, respectively (TIFF 550 kb)
345_2018_2370_MOESM6_ESM.tif (265 kb)
Figure S6 Funnel plots of the publication bias. A–D indicated funnel plots of IPSS, Qmax, PVR, and IIEF, respectively 6 (TIFF 265 kb)
345_2018_2370_MOESM7_ESM.doc (64 kb)
Table S1 PRISMA checklist (DOC 65 kb)
345_2018_2370_MOESM8_ESM.docx (18 kb)
Table S2 25-item CONSORT checklist (DOCX 19 kb)

References

  1. 1.
    Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, Oelke M, Tikkinen KAO, Gravas S (2015) EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67:1099–1109.  https://doi.org/10.1016/j.eururo.2014.12.038 CrossRefPubMedGoogle Scholar
  2. 2.
    Martin SA, Haren MT, Marshall VR, Lange K, Wittert GA (2011) Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men. World J Urol 29:179–184.  https://doi.org/10.1007/s00345-010-0605-8 CrossRefPubMedGoogle Scholar
  3. 3.
    Alawamlh OAH, Goueli R, Lee RK (2018) Lower urinary tract symptoms, benign prostatic hyperplasia, and urinary retention. Med Clin N Am 102:301–311.  https://doi.org/10.1016/j.mcna.2017.10.005 CrossRefPubMedGoogle Scholar
  4. 4.
    Ficarra V, Rossanese M, Zazzara M, Giannarini G, Abbinante M, Bartoletti R, Mirone V, Scaglione F (2014) The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy. Curr Urol Rep. 15:463.  https://doi.org/10.1007/s11934-014-0463-9 CrossRefPubMedGoogle Scholar
  5. 5.
    Yuan JQ, Mao C, Wong SY, Yang ZY, Fu XH, Dai XY, Tang JL (2015) Comparative effectiveness and safety of monodrug therapies for lower urinary tract symptoms associated with benign prostatic hyperplasia: a network meta-analysis. Medicine (Baltimore). 94:e974.  https://doi.org/10.1097/md.0000000000000974 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Gacci M, Sebastianelli A, Spatafora P, Corona G, Serni S, De Ridder D, Gravas S, Abrams P (2018) Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. Ther Adv Urol. 10:79–92.  https://doi.org/10.1177/1756287217742837 CrossRefPubMedGoogle Scholar
  7. 7.
    MacDonald R, Brasure M, Dahm P, Olson CM, Nelson VA, Fink HA, Risk MC, Rwabasonga B, Wilt TJ (2018) Efficacy of newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a systematic review. Aging Male.  https://doi.org/10.1080/13685538.2018.1434503 PubMedCrossRefGoogle Scholar
  8. 8.
    Thomas D, Chughtai B, Kini M, Te A (2017) Emerging drugs for the treatment of benign prostatic hyperplasia. Expert Opin Emerg Drugs. 22:201–212.  https://doi.org/10.1080/14728214.2017.1369953 CrossRefPubMedGoogle Scholar
  9. 9.
    Djavan B, Chapple C, Milani S, Marberger M (2004) State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 64:1081–1088.  https://doi.org/10.1016/j.urology.2004.07.031 CrossRefPubMedGoogle Scholar
  10. 10.
    van Dijk MM, de la Rosette JJ, Michel MC (2006) Effects of alpha(1)-adrenoceptor antagonists on male sexual function. Drugs 66:287–301CrossRefPubMedGoogle Scholar
  11. 11.
    Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L (2013) The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol 63:506–516.  https://doi.org/10.1016/j.eururo.2012.09.006 CrossRefPubMedGoogle Scholar
  12. 12.
    Taoka R, Kakehi Y (2017) The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. Asian J Urol. 4:158–163.  https://doi.org/10.1016/j.ajur.2017.02.004 CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M, Vignozzi L, Carini M, Vannelli GB, Maggi M (2011) Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 8:2746–2760.  https://doi.org/10.1111/j.1743-6109.2011.02416.x CrossRefPubMedGoogle Scholar
  14. 14.
    Wang XH, Wang X, Shi MJ, Li S, Liu T, Zhang XH (2015) Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and alpha-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH. Asian J Androl. 17:1022–1032.  https://doi.org/10.4103/1008-682x.154990 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M (2012) A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 61:994–1003.  https://doi.org/10.1016/j.eururo.2012.02.033 CrossRefPubMedGoogle Scholar
  16. 16.
    Oelke M, Shinghal R, Sontag A, Baygani SK, Donatucci CF (2015) Time to onset of clinically meaningful improvement with tadalafil 5 mg once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: analysis of data pooled from 4 pivotal, double-blind, placebo controlled studies. J Urol 193:1581–1589.  https://doi.org/10.1016/j.juro.2014.11.094 CrossRefPubMedGoogle Scholar
  17. 17.
    Takeda M, Yokoyama O, Yoshida M, Nishizawa O, Hirata K, Nakaoka R, Takita Y, Murakami M (2017) Safety and efficacy of the combination of once-daily tadalafil and alpha-1 blocker in Japanese men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a randomized, placebo-controlled, cross-over study. Int J Urol 24:539–547.  https://doi.org/10.1111/iju.13357 CrossRefPubMedGoogle Scholar
  18. 18.
    Karami H, Hassanzadeh-Hadad A, Fallah-Karkan M (2016) Comparing monotherapy with tadalafil or tamsulosin and their combination therapy in men with benign prostatic hyperplasia: a randomized clinical trial. Urol J. 13:2920–2926PubMedGoogle Scholar
  19. 19.
    Fawzi A, Kamel M, Salem E, Desoky E, Omran M, Elgalaly H, Sakr A, Maarouf A, Khalil S (2017) Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: a randomised, double-blind, placebo-controlled trial. Arab J Urol. 15:53–59.  https://doi.org/10.1016/j.aju.2016.11.001 CrossRefPubMedGoogle Scholar
  20. 20.
    Kumar S, Kondareddy C, Ganesamoni R, Nanjappa B, Singh SK (2014) Randomized Controlled trial to assess the efficacy of the combination therapy of alfuzosin and tadalafil in patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Low Urin Tract Symptoms. 6:35–40.  https://doi.org/10.1111/luts.12016 CrossRefPubMedGoogle Scholar
  21. 21.
    Regadas RP, Reges R, Cerqueira JB, Sucupira DG, Josino IR, Nogueira EA, Jamacaru FV, de Moraes MO, Silva LF (2013) Urodynamic effects of the combination of tamsulosin and daily tadalafil in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a randomized, placebo-controlled clinical trial. Int Urol Nephrol 45:39–43.  https://doi.org/10.1007/s11255-012-0317-7 CrossRefPubMedGoogle Scholar
  22. 22.
    Abolyosr A, Elsagheer GA, Abdel-Kader MS, Hassan AM, Abou-Zeid AM (2013) Evaluation of the effect of sildenafil and/or doxazosin on Benign prostatic hyperplasia-related lower urinary tract symptoms and erectile dysfunction. Urol Ann. 5:237–240.  https://doi.org/10.4103/0974-7796.120293 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Gacci M, Vittori G, Tosi N, Siena G, Rossetti MA, Lapini A, Vignozzi L, Serni S, Maggi M, Carini M (2012) A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Sex Med. 9:1624–1633.  https://doi.org/10.1111/j.1743-6109.2012.02718.x CrossRefPubMedGoogle Scholar
  24. 24.
    Ozturk MI, Kalkan S, Koca O, Gunes M, Akyuz M, Karaman MI (2012) Efficacy of alfuzosin and sildenafil combination in male patients with lower urinary tract symptoms. Andrologia. 44(Suppl 1):791–795.  https://doi.org/10.1111/j.1439-0272.2011.01268.x CrossRefPubMedGoogle Scholar
  25. 25.
    Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O, Atan A (2010) Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 28:17–22.  https://doi.org/10.1007/s00345-009-0484-z CrossRefPubMedGoogle Scholar
  26. 26.
    Bechara A, Romano S, Casabe A, Haime S, Dedola P, Hernandez C, Rey H (2008) Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med. 5:2170–2178.  https://doi.org/10.1111/j.1743-6109.2008.00940.x CrossRefPubMedGoogle Scholar
  27. 27.
    Kaplan SA, Gonzalez RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723.  https://doi.org/10.1016/j.eururo.2007.01.033 CrossRefPubMedGoogle Scholar
  28. 28.
    Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151:264–269, W64Google Scholar
  29. 29.
    Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:c869.  https://doi.org/10.1136/bmj.c869 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Zhang J, Yang B, Xiao W, Li X, Li H (2018) Effects of testosterone supplement treatment in hypogonadal adult males with T2DM: a meta-analysis and systematic review. World J Urol.  https://doi.org/10.1007/s00345-018-2256-0 CrossRefPubMedGoogle Scholar
  31. 31.
    Li X, Shen M, Cai H, Liu K, Liu Y, Huang Z, Liang C, Deng X, Ye J, Zou Q, Li J (2016) Association between manganese superoxide dismutase (MnSOD) polymorphism and prostate cancer susceptibility: a meta-analysis. Int J Biol Markers 31:e422–e430.  https://doi.org/10.5301/jbm.5000188 CrossRefPubMedGoogle Scholar
  32. 32.
    Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, Gluud LL, Als-Nielsen B, Gluud C (2009) Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses? Int J Epidemiol 38:276–286.  https://doi.org/10.1093/ije/dyn179 CrossRefPubMedGoogle Scholar
  33. 33.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560.  https://doi.org/10.1136/bmj.327.7414.557 CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials. 7:177–188CrossRefPubMedGoogle Scholar
  35. 35.
    DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 28:105–114.  https://doi.org/10.1016/j.cct.2006.04.004 CrossRefPubMedGoogle Scholar
  36. 36.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ. 315:629–634CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Uckert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol. 166:2484–2490CrossRefPubMedGoogle Scholar
  38. 38.
    Francis SH, Busch JL, Corbin JD, Sibley D (2010) cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 62:525–563.  https://doi.org/10.1124/pr.110.002907 CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Yokoyama O, Igawa Y, Takeda M, Yamaguchi T, Murakami M, Viktrup L (2015) Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. Ther Adv Urol. 7:249–264.  https://doi.org/10.1177/1756287215589238 CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Kolontarev K, Govorov A, Kasyan G, Priymak D, Pushkar D (2016) Current drug therapy of patients with BPH-LUTS with the special emphasis on PDE5 inhibitors. Cent Eur J Urol 69:398–403.  https://doi.org/10.5173/ceju.2016.879 CrossRefGoogle Scholar
  41. 41.
    Shim SR, Kim JH, Chang IH, Shin IS, Hwang SD, Kim KH, Yoon SJ, Song YS (2016) Is tamsulosin 0.2 mg effective and safe as a first-line treatment compared with other alpha blockers? A meta-analysis and a moderator focused study. Yonsei Med J 57:407–418.  https://doi.org/10.3349/ymj.2016.57.2.407 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Urology, Peking Union Medical College Hospital, Peking Union Medical CollegeChinese Academy of Medical SciencesBeijingChina
  2. 2.Department of Urology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer ResearchNanjing Medical University Affiliated Cancer HospitalNanjingChina
  3. 3.Department of UrologyDongtai People’s HospitalJiangsuChina
  4. 4.Department of Neurology, Peking Union Medical College Hospital, Peking Union Medical CollegeChinese Academy of Medical SciencesBeijingChina

Personalised recommendations